June 2026
Default mode network
What June 2026's 6 new studies found, synthesized from the papers below. All Default mode network research →
The synthesis
Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Default mode network, DMN, resting-state network, then ranked by relevance.
Research in June 2026 found that psychedelics (psilocybin, MDMA, LSD) consistently attenuate bottom-up signal flow and directionality within the default mode network (DMN) in both humans and mice, as shown by a multi-dataset analysis. One study also reported opposite reconfigurations of hierarchical brain dynamics between psilocybin and escitalopram in depression, suggesting distinct DMN-related mechanisms. However, the evidence is limited by small sample sizes, reliance on open-label or single-dose designs, and a lack of long-term follow-up data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem 2026 | double-blind randomized controlled trial | Mixed | Psilocybin and escitalopram produced opposite reconfigurations of hierarchical non-equilibrium brain dynamics, with baseline measures distinguishing responders from non-responders. | |
| Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice. 2026 | observational (multi-dataset analysis) | Supports | Psychedelics (MDMA, psilocybin, LSD) consistently attenuated bottom-up signal flow magnitude and directionality within the DMN across all drug-vs-control contrasts. |
Psilocybin and escitalopram produced opposite reconfigurations of hierarchical non-equilibrium brain dynamics, with baseline measures distinguishing responders from non-responders.
double-blind randomized controlled trial
Psychedelics (MDMA, psilocybin, LSD) consistently attenuated bottom-up signal flow magnitude and directionality within the DMN across all drug-vs-control contrasts.
observational (multi-dataset analysis)
Points of agreement
- Both studies indicate that psychedelics disrupt or reconfigure hierarchical processing within the DMN.
- The attenuation of bottom-up DMN propagations is consistent across multiple psychedelic compounds and species.
Conflicts
- Article 27705 found opposite DMN-related effects between psilocybin and escitalopram, while article 27746 focused only on psychedelics and did not compare to antidepressants.
- The specific direction of DMN change (e.g., increased vs. decreased hierarchical processing) may differ depending on the analytical approach (FDT vs. optical flow).
Gaps
- No studies examined long-term durability of DMN changes beyond acute drug effects.
- Sample sizes were not reported for the multi-dataset analysis, limiting assessment of statistical power.
- No studies in June 2026 directly linked DMN changes to clinical outcomes in patient populations.
- The role of dose, route of administration, and individual differences (e.g., personality, baseline DMN connectivity) remains unexplored.